10x Genomics $TXG Shares Sold by Janus Henderson Group PLC

Janus Henderson Group PLC lessened its holdings in 10x Genomics (NASDAQ:TXG) by 44.1% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 305,268 shares of the company’s stock after selling 240,558 shares during the period. Janus Henderson Group PLC owned approximately 0.24% of 10x Genomics worth $6,481,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of TXG. Geneos Wealth Management Inc. purchased a new stake in shares of 10x Genomics during the fourth quarter worth $38,000. Larson Financial Group LLC boosted its holdings in 10x Genomics by 164.4% in the fourth quarter. Larson Financial Group LLC now owns 2,364 shares of the company’s stock valued at $39,000 after purchasing an additional 1,470 shares during the period. Fifth Third Bancorp acquired a new position in 10x Genomics during the 1st quarter worth $50,000. Van ECK Associates Corp grew its stake in 10x Genomics by 85.9% during the 4th quarter. Van ECK Associates Corp now owns 3,668 shares of the company’s stock worth $60,000 after purchasing an additional 1,695 shares in the last quarter. Finally, EverSource Wealth Advisors LLC increased its holdings in 10x Genomics by 203.9% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 7,490 shares of the company’s stock worth $87,000 after purchasing an additional 5,025 shares during the period. Institutional investors and hedge funds own 84.68% of the company’s stock.

Insiders Place Their Bets

In related news, CFO Adam Taich sold 15,098 shares of the company’s stock in a transaction that occurred on Friday, May 22nd. The stock was sold at an average price of $24.44, for a total value of $368,995.12. Following the completion of the transaction, the chief financial officer directly owned 379,898 shares of the company’s stock, valued at $9,284,707.12. This represents a 3.82% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Benjamin J. Hindson sold 11,595 shares of the stock in a transaction that occurred on Friday, May 22nd. The shares were sold at an average price of $24.44, for a total transaction of $283,381.80. Following the completion of the transaction, the insider owned 502,000 shares in the company, valued at $12,268,880. This represents a 2.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 91,309 shares of company stock worth $2,581,357 in the last three months. 8.84% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. Piper Sandler increased their price target on 10x Genomics from $20.00 to $42.00 and gave the company a “neutral” rating in a research report on Wednesday, July 1st. Citigroup boosted their price objective on 10x Genomics from $24.00 to $45.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 8th. Weiss Ratings restated a “sell (d-)” rating on shares of 10x Genomics in a research note on Wednesday, June 24th. JPMorgan Chase & Co. raised their target price on shares of 10x Genomics from $17.00 to $20.00 and gave the company a “neutral” rating in a report on Tuesday, May 12th. Finally, Barclays lifted their price target on shares of 10x Genomics from $30.00 to $40.00 and gave the stock an “overweight” rating in a research note on Wednesday, June 24th. Four research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, 10x Genomics currently has a consensus rating of “Hold” and an average target price of $32.08.

10x Genomics Price Performance

10x Genomics stock opened at $45.60 on Friday. The stock has a market cap of $5.79 billion, a PE ratio of -268.24 and a beta of 2.03. The stock’s fifty day moving average is $38.81 and its two-hundred day moving average is $27.45. 10x Genomics has a 1-year low of $11.16 and a 1-year high of $50.34.

10x Genomics (NASDAQ:TXG) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.10. 10x Genomics had a negative return on equity of 2.86% and a negative net margin of 3.55%.The business had revenue of $151.04 million during the quarter, compared to analysts’ expectations of $146.67 million. During the same period in the prior year, the firm posted $0.28 EPS. The business’s quarterly revenue was down 12.7% compared to the same quarter last year. On average, research analysts expect that 10x Genomics will post -0.78 earnings per share for the current fiscal year.

10x Genomics News Summary

Here are the key news stories impacting 10x Genomics this week:

• Positive Sentiment: Adjusted loss was $0.14 per share, better than the consensus loss estimate of $0.24, while revenue of $151.0 million exceeded expectations of approximately $146.7 million. 10x Genomics Reports Q2 Loss, Tops Revenue Estimates
• Positive Sentiment: Management raised its full-year 2026 revenue outlook to $610 million-$630 million. The midpoint is broadly in line with the analyst consensus of $613.8 million, suggesting some improvement in visibility rather than a major forecast reset. 10x Genomics Raises 2026 Revenue Outlook
• Neutral Sentiment: Atera shipments remain at approximately 40 units, indicating continued customer adoption of the company’s newer spatial biology platform, although the update does not signal a significant acceleration in deployments. 10x Genomics Q2 2026 Earnings Call Transcript
• Negative Sentiment: Quarterly revenue declined 12.7% from the prior year, and the company remained unprofitable, reporting a net loss, negative net margin and negative return on equity. EPS also deteriorated from earnings of $0.28 in the year-earlier quarter to a loss of $0.14. 10x Genomics Reports Second Quarter 2026 Financial Results

10x Genomics Company Profile

10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.